T. F. Zioncheck

T. Zioncheck, L. Richardson, Y. Xuè, 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Heparin induces dimerization and confers proliferative activity onto the hepatocyte growth factor antagonists NK1 and NK2

K. Bauer, K. Hillan, P. Godowski, 1996, The Journal of cell biology.

Analysis of Biological Effects and Signaling Properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2)

N. Ferrara, J. Lecouter, B. Moffat, 2001, The Journal of Biological Chemistry.

KDR (VEGF Receptor 2) Is the Major Mediator for the Hypotensive Effect of VEGF

A. D. de Vos, Renhui Yang, A. Ogasawara, 2002, Hypertension.

Cloning of a type I TGF-beta receptor and its effect on TGF-beta binding to the type II receptor.

R. Derynck, L. Shum, R. Ebner, 1993, Science.

In vivo activity of novel capecitabine regimens alone and with bevacizumab and oxaliplatin in colorectal cancer xenograft models

D. Heimbrook, B. Higgins, K. Kolinsky, 2009, Molecular Cancer Therapeutics.

Vascular endothelial growth factor-mediated endothelium-dependent relaxation is blunted in spontaneously hypertensive rats.

S. Bunting, A. Yim, A. Furnary, 2001, The Journal of pharmacology and experimental therapeutics.

Expression and characterization of hepatocyte growth factor receptor-IgG fusion proteins. Effects of mutations in the potential proteolytic cleavage site on processing and ligand binding.

P. Godowski, M. Mark, N. Lokker, 1992, The Journal of biological chemistry.

Vascular Endothelial Growth Factor-Induced Nitric Oxide- and PGI2-Dependent Relaxation in Human Internal Mammary Arteries: A Comparative Study with KDR and Flt-1 Selective Mutants

A. Yim, Hongkui Jin, T. Zioncheck, 2004, Journal of cardiovascular pharmacology.

Phosphorylation and activation of p40 tyrosine kinase by casein kinase‐1

E. Itarte, M. Weber, J. Vila, 1990, FEBS letters.

Hepatocyte Growth Factor/Scatter Factor

R. Schwall, T. Zioncheck, L. Richardson, 2002 .

Exaggerated Hypotensive Effect of Vascular Endothelial Growth Factor in Spontaneously Hypertensive Rats

Renhui Yang, A. Ogasawara, S. Bunting, 2002, Hypertension.

Substantially attenuated hemodynamic responses to Escherichia coli-derived vascular endothelial growth factor given by intravenous infusion compared with bolus injection.

B. Keyt, R. Yang, S. Bunting, 1998, The Journal of pharmacology and experimental therapeutics.

Vascular Endothelial Growth Factor Governs Endothelial Nitric-oxide Synthase Expression via a KDR/Flk-1 Receptor and a Protein Kinase C Signaling Pathway*

D. Y. Lee, T. Zioncheck, Ben-Quan Shen, 1999, The Journal of Biological Chemistry.

The cytoplasmic domain of tissue factor is phosphorylated by a protein kinase C-dependent mechanism.

S. Roy, G. Vehar, T. Zioncheck, 1992, The Journal of biological chemistry.

Development of tricalcium phosphate/amylopectin paste combined with recombinant human transforming growth factor beta 1 as a bone defect filler.

G Osaka, G. Osaka, L. Deguzman, 1997, Journal of biomedical materials research.

Generation of an active protein-tyrosine kinase from lymphocytes by proteolysis.

R. Geahlen, T. Zioncheck, M. Harrison, 1988, The Journal of biological chemistry.

Purification and characterization of a protein-tyrosine kinase from bovine thymus.

R. Geahlen, T. Zioncheck, M. Harrison, 1986, The Journal of biological chemistry.

Phosphorylation of glycogen synthase by a bovine thymus protein-tyrosine kinase, p40.

R. Geahlen, A. Depaoli-Roach, P. Roach, 1988, Biochemical and biophysical research communications.

Tyrosine phosphorylation of band 3 inhibits peripheral protein binding.

P. Low, R. Geahlen, B. Willardson, 1987, The Journal of biological chemistry.

The pharmacokinetics, tissue localization, and metabolic processing of recombinant human hepatocyte growth factor after intravenous administration in rats.

P. Godowski, N. Modi, T. Zioncheck, 1994, Endocrinology.